In summary, when compared to single agent treatment, the combination treatment with TKI and ABT-737 induced maximal apoptosis in imatinib-resistant primary CML cells especially in those that harbored the BIM deletion polymorphism. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.